GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » Piotroski F-Score

IDEXX Laboratories (IDEXX Laboratories) Piotroski F-Score : 7 (As of Apr. 27, 2024)


View and export this data going back to 1991. Start your Free Trial

What is IDEXX Laboratories Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

IDEXX Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for IDEXX Laboratories's Piotroski F-Score or its related term are showing as below:

IDXX' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of IDEXX Laboratories was 9. The lowest was 5. And the median was 7.


IDEXX Laboratories Piotroski F-Score Historical Data

The historical data trend for IDEXX Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Piotroski F-Score Chart

IDEXX Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 7.00 7.00 5.00 7.00

IDEXX Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 7.00 8.00 7.00

Competitive Comparison of IDEXX Laboratories's Piotroski F-Score

For the Diagnostics & Research subindustry, IDEXX Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 214.054 + 224.236 + 212.231 + 194.521 = $845 Mil.
Cash Flow from Operations was 183.912 + 200.314 + 272.433 + 249.851 = $907 Mil.
Revenue was 900.195 + 943.63 + 915.527 + 901.601 = $3,661 Mil.
Gross Profit was 542.971 + 572.85 + 547.982 + 526.167 = $2,190 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(2746.765 + 2808.398 + 2870.806 + 3086.404 + 3259.925) / 5 = $2954.4596 Mil.
Total Assets at the begining of this year (Dec22) was $2,747 Mil.
Long-Term Debt & Capital Lease Obligation was $723 Mil.
Total Current Assets was $1,495 Mil.
Total Current Liabilities was $952 Mil.
Net Income was 193.965 + 131.979 + 180.938 + 172.207 = $679 Mil.

Revenue was 836.549 + 860.546 + 841.661 + 828.568 = $3,367 Mil.
Gross Profit was 498.753 + 514.032 + 506.626 + 484.927 = $2,004 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(2437.203 + 2592.689 + 2607.185 + 2640.067 + 2746.765) / 5 = $2604.7818 Mil.
Total Assets at the begining of last year (Dec21) was $2,437 Mil.
Long-Term Debt & Capital Lease Obligation was $796 Mil.
Total Current Assets was $1,101 Mil.
Total Current Liabilities was $1,236 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

IDEXX Laboratories's current Net Income (TTM) was 845. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

IDEXX Laboratories's current Cash Flow from Operations (TTM) was 907. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=845.042/2746.765
=0.30764991

ROA (Last Year)=Net Income/Total Assets (Dec21)
=679.089/2437.203
=0.27863457

IDEXX Laboratories's return on assets of this year was 0.30764991. IDEXX Laboratories's return on assets of last year was 0.27863457. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

IDEXX Laboratories's current Net Income (TTM) was 845. IDEXX Laboratories's current Cash Flow from Operations (TTM) was 907. ==> 907 > 845 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=722.554/2954.4596
=0.24456385

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=795.626/2604.7818
=0.30544823

IDEXX Laboratories's gearing of this year was 0.24456385. IDEXX Laboratories's gearing of last year was 0.30544823. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=1495.254/951.547
=1.57139269

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=1101.477/1235.803
=0.89130468

IDEXX Laboratories's current ratio of this year was 1.57139269. IDEXX Laboratories's current ratio of last year was 0.89130468. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

IDEXX Laboratories's number of shares in issue this year was 83.942. IDEXX Laboratories's number of shares in issue last year was 83.826. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2189.97/3660.953
=0.5981967

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2004.338/3367.324
=0.5952317

IDEXX Laboratories's gross margin of this year was 0.5981967. IDEXX Laboratories's gross margin of last year was 0.5952317. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=3660.953/2746.765
=1.33282352

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=3367.324/2437.203
=1.3816346

IDEXX Laboratories's asset turnover of this year was 1.33282352. IDEXX Laboratories's asset turnover of last year was 1.3816346. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

IDEXX Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

IDEXX Laboratories  (NAS:IDXX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


IDEXX Laboratories Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEXX Laboratories (IDEXX Laboratories) Business Description

Address
One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Executives
James F Polewaczyk officer: Corporate Vice President IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky director, officer: President and CEO ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith officer: Executive Vice President C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers director, officer: President & CEO IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane officer: Executive Vice President C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt director CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin director 7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley director C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak director C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg officer: EVP, GC & Corporate Secretary EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek director 6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451